Diagnosed anxiety
A clinical treatment claim needs a defined diagnosis, suitable comparator, validated scale, meaningful follow-up and adverse-event reporting.
Evidence profile · O-002
Selank: anxiety claims and evidence
A small regional trial is a signal, not a treatment standard. The published human literature is limited and does not establish consumer sprays for anxiety or general mood improvement.
Selank has small human studies involving anxiety-spectrum conditions, but the evidence remains low certainty and regionally concentrated. The available reports do not provide a large, independently replicated, placebo-controlled programme that establishes routine anxiety treatment, mood enhancement or the effectiveness of a product sold online.
Selank is described as a synthetic analogue related to tuftsin. Its mechanism, a symptom-scale change and a consumer promise are different evidence layers. Product identity, formulation, nasal delivery and safety also need evidence that a paper about the compound cannot supply.
Claim separation
Anxiety, mood and stress are not one outcome
Stress or calm
Short-term self-reported calm in a selected setting is not evidence for treating an anxiety disorder.
Mood enhancement
Anxiety scales do not establish antidepressant benefit, resilience, cognition or daily performance.
Product claim
A study cannot verify a separate spray’s identity, amount, stability, delivery uniformity or microbiological quality.
Human evidence
What the reported studies can support
| Report | Population | Finding level | Limit |
|---|---|---|---|
| 2008 clinical report | 62 people with generalised anxiety disorder or neurasthenia; 30 received Selank | Reported symptom and biological observations | Small, regional report with limited information for independent appraisal |
| 2015 combination study | Anxiety-spectrum disorders treated with a benzodiazepine combination strategy | Reported possible benefit in a combined regimen | Cannot isolate broad Selank effectiveness or support self-treatment |
| Mechanistic studies | Laboratory, animal or brain-network research | Biological plausibility | Does not establish clinical anxiety benefit |
Evidence quality
What a dependable replication programme would add
Useful replication would involve independent teams, prospectively registered protocols, concealed allocation, credible blinding, a suitable placebo and outcomes selected before results were known. It would report dropouts, concomitant medicines, adverse events and the size of benefit, not only statistical significance.
Translation and indexing also matter. Brief abstracts can omit methods needed to judge bias. A second publication from a related team or a different mechanism experiment does not resolve those gaps.
Safety and product
Sparse adverse-event reporting does not establish safety
The FDA’s current compounding safety page says Selank acetate may present immunogenicity concerns related to aggregation and peptide impurities, and that important human safety information is lacking. This is a data-gap finding, not proof that every exposure causes harm.
A consumer nasal product also needs a stable formulation, appropriate container, consistent delivered amount and microbiological control. An injectable presentation raises separate sterility, endotoxin and particulate questions.
Clinical comparison matters as much as mechanism. Anxiety disorders have established psychological and medical treatments with known monitoring pathways. A small Selank report would need to show a clinically important advantage, an acceptable harm profile and reproducibility before it could change that decision context. Evidence for an add-on regimen cannot be treated as evidence that Selank should replace established care.
Clinical questionBenefit versus placebo
Safety questionExposure and surveillance
Product questionBatch and delivery system
Regulatory questionExact jurisdiction
Decision boundary
What remains unknown
Future evidence would be most useful if it separates diagnosed anxiety from general stress, selects one primary patient-important outcome and compares a characterised Selank product with a credible placebo and current care. Follow-up should be long enough to show whether benefit persists and whether stopping, rebound or delayed harms occur. Results should be reported whether positive, negative or inconclusive.
- Whether Selank improves diagnosed anxiety in large, independently replicated trials.
- Whether any effect is clinically important and durable after treatment ends.
- How Selank compares with established psychological and medical treatments.
- The frequency of uncommon immune, neurological or psychiatric harms.
- Whether different salts, formulations and delivery devices produce comparable exposure.
- Whether a specific spray or vial contains stable Selank at the stated amount.
Evidence ledger
Sources and limits
These sources define the conclusions on this page. A citation supports only the proposition stated beside it.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| PubMed: 2008 Selank clinical report | A small human study reported outcomes in generalised anxiety disorder and neurasthenia. | The abstract does not establish a modern, independently replicated treatment programme. | |
| PubMed: 2015 Selank combination study | A regional report examined Selank alongside benzodiazepine treatment in anxiety-spectrum disorders. | A combination study cannot establish Selank alone or a consumer spray. | |
| FDA: bulk-substance safety risks | FDA identifies limited human safety information and possible impurity or immunogenicity concerns for Selank acetate. | It does not determine clinical effectiveness or quantify risk. | |
| MHRA products database | The official route to check current UK marketing authorisations. | It does not verify a seller’s label or product content. |
Continue the investigation
Read the connected evidence
- the anxiety claims we have assessedPlace Selank beside other mood claims without transferring conclusions between compounds.
- how we assess human evidenceSee how replication, directness and reporting affect certainty.
- UK peptide regulationCheck the status of the exact product and presentation.
- known versus unknown risksSeparate observed adverse events from gaps in exposure and surveillance.
Quick answers
Frequently asked questions
Does Selank treat anxiety?
Small regional reports describe possible effects, but dependable independently replicated evidence for routine anxiety treatment remains insufficient.
Is Selank the same as an established anxiety medicine?
No. It does not have the same evidence base, authorised indications or routine clinical role as established treatments.
Does a brain-network effect prove symptom relief?
No. A biological or imaging signal can support a mechanism hypothesis without proving a clinically important anxiety benefit.
Is Selank authorised in the UK?
No UK marketing authorisation was identified under the Selank name. Check the current MHRA products database for the exact product.
Is a nasal spray safer than an injection?
The risk questions differ, but nasal delivery still needs formulation, dose-uniformity and microbiological controls. Sparse reporting does not establish safety.
What remains unknown?
Independent replication, durable comparative benefit, uncommon harms and the identity and quality of individual products remain uncertain.
Evidence library
Claim-level evidence records
Open the individual records behind this profile. Each record links to the primary and official sources used for its verdict.
Profile-to-record links checked 10 August 2026. These evidence records received named scientific and clinical sign-off on 10 August 2026.
Editorial experience
From our work: how we checked this page
For topical-map item O-002, Selank evidence: anxiety claims and trial limits was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 4 unique external sources and 8 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.